Introduction
The central hypothesis underlying specific anti-leukemia immunotherapy is that leukemic cells express antigenic determinants not expressed on their normal counterpart adult cells. Those antigenic determinants must be immunogenic for an effective attack by the immune system. 1, 2 Anecdotal evidence that the immune system may help to eradicate leukemia is provided by occasional reports of improved survival following post-induction immunization with non-specific immunostimulators, [3] [4] [5] although convincing evidence is still lacking. The graft versus leukemia (GVL) phenomenon after allogeneic bone marrow transplantation (BMT) is the most striking evidence of a role of the immune system in controlling leukemia. 6, 7 Alloreactive T cells are not the only mediators of the GVL effect; graft-versus-host disease (GVHD) and GVL may, therefore, be separable. 8 Several studies have shown that lymphokine-activated killer cells (LAK) from patients with acute leukemia lyse autologous blast cells. [9] [10] [11] [12] [13] Contrasting allogeneic anti-leukemia CTLs, only a few reports about allogeneic anti-leukemic cytotoxic T lymphocytes (CTLs) have been published, 14, 15 suggesting impaired leukemia-specific immune responses in leukemic patients. 16, 17 Possible targets for such an immune response might be the p210 product of the bcr/abl rearrangement, PML/RAR peptides, p53 mutations, and EBNA-1.
Cancer evolves from a series of mutational events within a cell that can result in the production of genetically altered proteins. 18 Peptides from these mutated proteins may bind to major histocompatibility complex (MHC) class I molecules, and in this context, may serve as targets for specific cytotoxic T cells (CTL). 19 Tumor-associated antigens that provoke tumor rejection in the host have been demonstrated in experimentally, chemically, and virally induced tumors. But in most experimental, spontaneous tumor systems (resembling the situation found in most patients), tumor-associated antigens usually cannot be detected. Recent experiments have shown that several poorly immunogenic solid tumors can be recognized by MHC-class restricted CD8
+ CTL if the tumors are engineered to secrete one of several cytokines or costimulatory molecules. [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] In addition, secretion of cytokines by the tumor cells stimulated the host's immune system to identify and kill the untransduced parental cells upon reimplantation; and even more, a rejection of established cancer can occur by inducing a systemic anticancer immune response by vaccination with cytokine-transduced tumor cells. 21, [22] [23] [24] [25] [26] [27] [28] [29] [30] Leukemic cells may escape immune surveillance by not expressing leukemia-specific antigens or by not expressing signals that are essential for activation of the host immune system. 31 At the molecular level, the defective signaling of leukemic cells might be attributable to (1) down-regulation of major histocompatibility complex (MHC) molecules; (2) alteration of antigen-presenting pathways, resulting in an inability to present tumor-specific antigens to host T cells; (3) absence of costimulatory or adhesion molecules that are essential for activation of the host immune system; or (4) production of factors that modify host immune responses.
Murine models have shown IL-2 to be effective in preventing relapse after BMT in a B cell leukemia (BCL1); 32 combined IL-1/IL-2 therapy inhibited metastatic tumor growth of Friend erythroleukemia cells (FLC); 33 continuous coadministration of M-CSF and IL-2 protected mice against a lethal dose of T cell leukemic cells (EL4); 34 IFN-alpha gene transfer into Friend erythroleukemia cells (FLC) abrogated tumorigenicity, and injections of those IFN-alpha producing cells were effective in inhibiting tumor growth in mice with established metastatic tumors. 35 These described murine tumor models used virally or chemically induced cancers, which are already immunogenic to begin with. 26 We have developed a model system to study this tumor-vaccination approach using a nonimmunogenic murine myeloid leukemia which spontaneously arose (WEHI3) to test the hypothesis that a non-immunogenic leukemia can be used in the development of a leukemia vaccine.
Materials and methods

Mice
Pathogen-free female BALB/c mice, 10-14 weeks old, were obtained from Harlan-Sprague Dawley (Indianapolis, IN, USA).
WEHI3
WEHI3, a rapidly fatal acute myelomonocytic leukemia, spontaneously developed is of Balb/c origin: the cells are nonimmunogenic and express class I MHC molecules. 36 The cell line was obtained from ATCC (Rockville, MD, USA) and was maintained in IMDM/10% fetal calf serum (FCS). Cells were washed three times in PBS before being injected into mice.
Retroviral vectors
One vector used for transduction contained the LN-based G1Nab CVhIL-2 construct (titer range 1-5 × 10 4 c.f.u./ml) in which the neoR selectable marker was driven by the Moloney murine leukemia virus long terminal repeat (LTR), and the human IL-2 cDNA was driven by the cytomegalovirus (CV) early enhancer/promoter. The vector was provided as frozen supernatant from Genetic Therapy (Gaithersburg, MD, USA). The JZEN hIL-7/tk neo (titer range 1-10 × 10 6 c.f.u./ml) was constructed with the neoR gene driven by the thymidine kinase promoter, and the hIL-7 cDNA was under the transcriptional control of the myeloproliferative sarcoma virus LTR (Graeme J Dougherty, Terry Fox Lab., Vancouver, Canada). 37 This construct was packaged in the GP + env AM 12 amphotrophic cell line and subcloned to produce high-titer stocks. 38 The MGF-mGM-CSF vector was MoMLV-derived, without any selectable marker sequences, encoding murine GM-CSF; a high-titer packaging cell line psi-CRIP was kindly provided by Richard Mulligan (Whitehead Institute, Cambridge, MA, USA).
Gene transfer About 1-2 × 10 6 exponentially growing leukemic target cells were grown in 10 ml supernatant of high-titer retroviralpackaging cell lines in the presence of 4-8 g/ml polybrene for 2-18 h. Following selection in cultures containing the neomycin-analog G418 (0.5-1.0 mg/ml bioactive G418) for 1-2 weeks, the surviving successfully transduced cells were subcloned by methylcellulose soft-gel culture. Individual colonies were plucked and expanded in liquid culture. Using ELISA assays (hIL-2-and hIL-7-Quantikine; R+D Systems, Minneapolis, MN, USA) to measure the protein expression, high/low cytokine-producing clones were identified, expanded, and viably frozen. The MGF vector does not use any selectable marker; therefore, directly after transduction, the leukemic cells were cloned in soft-gel culture and tested for mGM-CSF production using an ELISA assay. Transduction efficacy was 15%.
Vaccination and leukemia challenge
Either cytokine-producing leukemic cells or a mixture of cytokine-producing NIH-3T3 fibroblasts with unaltered parental leukemic cells were used for immunization. After irradiation (WEHI3: 1000 rad; NIH-3T3-fibroblasts: 10 000 rad) to inhibit in vivo growth while preserving cytokine production, the vaccine preparation was injected s.c. every 7 days for up to 4 weeks. One week later, mice were challenged s.c. or i.v. with non-transduced, parental leukemic cells. Mice were followed for development of leukemia and survival. 
100% survival
The data represent the medium time in days to death due to leukemia for four mice per i.v. inoculum of WEHI3 leukemia cells into syngeneic Balb/c mice.
Vaccination as treatment for leukemia
The same vaccination schedule as used for preimmunization studies was started 3 days after i.v. injection of 5 × 10 4 WEHI3 cells per mouse, with 10 mice per group. Mice were followed for development of leukemia and survival.
Statistical analysis
The survival of the different subgroups was expressed as Kaplan-Meier curves, followed by comparisons using the logrank 2 test with corresponding P values. A P value below 0.05 indicates significant different survival times of different subgroups.
Results
Murine leukemia models
Survival of mice injected with increasing i.v. doses of syngeneic leukemia cells is shown in Table 1 .
Leukemia vaccines
The WEHI3 leukemia line was transduced with the JZEN hIL-7/tk neo, only the neoR-encoding control retroviral vectors, or with the MGF-mGM-CSF vector. The cytokine production of 10 6 cells/24 h from stably transduced subclones and a subclone of NIH-3T3 fibroblasts, transduced with the G1Na CVhIL-2 retroviral vector is shown in Table 2 . Characterization of these subclones showed no difference in either their Table 2 Subclones genetically engineered to produce hIL-2, hIL-7, or mGM-CSF Vaccination studies 
Discussion
We have shown that transduction of the non-or low-immunogenic murine leukemia line WEHI3 with the gene for human IL-7 elicits a systemic anti-leukemic immune response and causes rejection of leukemia in 43% of vaccinated syngeneic hosts. This effect was dose-dependent; only leukemic cells expressing high levels of IL-7, as compared to lower level producers, stimulated an immune response. To rule out the possibility that the differences in vaccination potential of WEHI3 clones 2 and 23 is due to properties intrinsic to individual clones rather than the secreted IL-7, we vaccinated with a polyclonal IL-7-transduced population as well.
Using the same vaccination approach with a mixture of hIL-2-producing NIH-3T3 'bystanding' fibroblasts with parental WEHI3 leukemic cells, we saw a protective immune response against WEHI3 leukemia. The observation that the protective vaccination effects vanished with a 10-fold increase of local IL-2 production at the vaccination site is in accord with previous reports of an 'optimal dose' of local IL-2 production with no protective effect either below or above this 'window'. 39 The mGM-CSF has been reported to be the most effective cytokine in some cancer vaccine models. 26 However, in our model, vaccination with mGM-CSF-producing WEHI3 cells resulted in only 20% survival of i.v. challenged mice, and the combination of mGM-CSF-, IL-2-and IL-7-producing vaccines did not lead to either additive or synergistic effects. The level of mGM-CSF production in WEHI cells is less than what has been seen in other cell lines using MFG-based vectors. This is most likely due to an expression problem in WEHI3 cells. Therefore, it is conceivable that increases in the expression of mGM-CSF in this system still might result in more effective immunization.
No differences in development of leukemia and survival times could be detected when non-irradiated, viable, IL-7-and mGM-CSF-producing WEHI3 cells were injected i.v. as compared to the unaltered parental leukemia cells, demonstrating the absence of any immediate strong immune response. However, within 4 weeks, the mice could be successfully pre-immunized with irradiated cytokine-producing leukemic cells, indicating that low-immunogenic murine leukemia cells can be rendered immunogenic to some extent by this transduction/vaccination approach. This vaccination strategy, used as treatment for pre-established leukemia was unsuccessful. No significant difference in development of leukemia survival was detected between treated and control groups. Two explanations for this outcome are possible: (1) the levels of either the T cell growth factors (IL-2, IL-7) and/or potential enhancement of antigen presentation (GM-CSF) may not have been great enough to amplify any inherent immune response or break possible immuno-tolerance; and (2) the leukemia developed too rapidly to give an emerging immune response a period of time to prevent progression of the leukemia. Other models of immune modulation of leukemia showed effectiveness only in the state of 'minimal disease'. 40 Taken together, we identified IL-7 and IL-2 as effective cytokines in our non-immunogenic WEHI3 leukemia/vaccination model, with only marginal immunostimulation by GM-CSF. Immunizing mice with a pre-established leukemia burden did not cure or result in a prolongation of survival, indicating that improved methods of immunization are needed.
